
Targeting Neurotherapeutic Agents Through the Blood-Brain Barrier
William M. Pardridge, MD
Arch Neurol. 2002;59:35-40.
The blood-brain barrier (BBB) is maintained by the endothelial tight
junctions within the brain microvasculature. Most small-molecule neuropharmaceutical
agents and virtually all large-molecule drugs do not cross the BBB. The BBB
problem is the rate-limiting factor preventing the transfer of progress in
the molecular neurosciences to the development of clinically effective neurotherapeutic
agents. The future development of neurotherapeutic agents will be accelerated
by the development of BBB drug-targeting technology.
From the Department of Medicine, University of California, Los Angeles,
UCLA School of Medicine.
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(1):155-157.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Biotinylation Facilitates the Uptake of Large Peptides by Escherichia coli and Other Gram-Negative Bacteria
Walker and Altman
Appl. Environ. Microbiol. 2005;71:1850-1855.
ABSTRACT
| FULL TEXT
Attenuated Central Nervous System Infection in Advanced HIV/AIDS With Combination Antiretroviral Therapy
McArthur et al.
Arch Neurol 2004;61:1687-1696.
ABSTRACT
| FULL TEXT
Through a Glass, Darkly: Cerebrospinal Fluid Viral Load Measurements and the Pathogenesis of Human Immunodeficiency Virus Infection of the Central Nervous System
Tyler and McArthur
Arch Neurol 2002;59:909-912.
FULL TEXT
Experimental Neurotherapeutics: Leaps and Bounds
Shoulson
Arch Neurol 2002;59:689-691.
FULL TEXT
|